Prof riccardo lencioni biography

Lencioni is director, Division of Diagnostic Imaging and Intervention, Pisa University Hospital and School of Medicine, Pisa, Italy.
Riccardo LENCIONI, Full Professor | Cited by 45209 | of University of Pisa, Pisa (UNIPI) | Read 470 publications | Contact Riccardo LENCIONI.
2024 Course Directors Riccardo Lencioni, MD, FSIR, EBIR (VIEW BIO) Professor of Radiology University of Pisa, Italy Honorary Research Professor Miami Cancer.

•

Riccardo Lencioni

Could you name one moment in the history of interventional oncology that you look back at and think, “wow”?

I remember how it all started. The meetings organised in the early 90s during the RSNA by a small group of pioneers. We used to meet at Gino’s Pizza in Chicago: there were no sponsors at that time, we did not have the money to book a conference room! But the enthusiasm was unbelievable, we had the feeling that something was happening. And I still recall when— few years later—we agreed that the time was come to give a name to the growing number of vascular and non-vascular interventions increasingly used in cancer treatment. It was the birth of interventional oncology.

What are the three most interesting current trials in hepatocellular carcinoma that you are waiting to see the results of?

I think one of the most important areas for research in hepatocellular carcinoma is to explore the synergies between locoregional interventional treatments—ablation or chemoembolization—and systemically-administered drugs. If I have to mention three key trials that

•

Dr Lencioni on Unmet Needs in Unresectable HCC

Riccardo Lencioni, MD, FSIR, EBIR, professor, director, Diagnostic Imaging and Intervention, Pisa University School of Medicine, discusses unmet needs in patients with unresectable hepatocellular carcinoma (HCC).

Although the HCC treatment armamentarium has substantially expanded in recent years, this disease remains challenging to manage, as patients continue to have a poor prognosis, Lencioni begins. A multidisciplinary approach is crucial to improving patient outcomes, he states. This involves a comprehensive assessment of all available therapies, including surgery, transplantation, ablation, embolization therapies, and the emerging field of immunotherapy-based systemic treatments, he details.

Lencioni states that it is essential to recognize that patients with HCC often face 2 concurrent challenges: managing the tumor itself and addressing underlying chronic liver disease. Therefore, patient selection is paramount, with careful consideration given to liver function and the risk of bleeding. Each patient's unique characteri

•

Liver Cancer. 2014 May 21;3(2):133–281.

Open in a new tab

Name	Masatoshi Kudo, MD, PhD
Institution	Professor and Chairman, Department of Hepatology and Gastroenterology, Kinki University School of Medicine; President, Kinki University Medical Center

Open in a new tab

Masatoshi Kudo studied Medicine at Kyoto University and graduated in 1978. Following this, he completed a clinical fellowship in Kobe City General Hospital followed by a research fellowship at the University of California Davis Medical Center in USA and Kyoto University Graduate School of Medicine, where he received his PhD degree in Medical Science in 1987. Professor Kudo is currently a Professor and Chairman at the Department of Gastroenterology and Hepatology, Kinki University School of Medicine since 1999 and a President of Kinki University Medical Center since 2008.

Professor Kudo has published 476 International scientific peer review papers in well-regarded journals in addition to 786 domestic scientific papers. He has given 297 invited lectures in the area of his expertise on numerous occ